<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389244</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0150/1309</org_study_id>
    <secondary_id>2013-003910-42</secondary_id>
    <nct_id>NCT02389244</nct_id>
  </id_info>
  <brief_title>A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas</brief_title>
  <acronym>REGOBONE</acronym>
  <official_title>A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INDICATION:&#xD;
&#xD;
      Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone,&#xD;
      intermediate or high-grade chondrosarcomas and chordomas and either bone or soft tissue&#xD;
      metastatic CIC-rearranged sarcomas&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODOLOGY:&#xD;
&#xD;
      Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind&#xD;
      placebo-controlled trial, with 5 cohorts: cohort A: Osteosarcoma, cohort B: Ewing sarcoma,&#xD;
      cohort C: Chondrosarcoma, cohort D : chondroma, cohort E: CIC-rearranged sarcoma. Cohort A, B&#xD;
      and C will involve a total of 36 patients (24 Regorafenib + 12 placebo), cohort D a total of&#xD;
      24 evaluable patients (16 Regorafenib + 8 placebo) and cohort E will involve a total of 27&#xD;
      evaluable patients (18 Regorafenib + 9 placebo).&#xD;
&#xD;
      159 patients who meet the eligibility criteria will be randomly assigned in a 2:1 ratio to&#xD;
      the following treatment groups :&#xD;
&#xD;
      The Arm A:&#xD;
&#xD;
      Regorafenib (160 mg/d) once daily for the 3 weeks on / 1 week off plus Best Supportive Care&#xD;
      (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .&#xD;
&#xD;
      Patients receiving regorafenib who experience disease progression and for whom in the&#xD;
      investigator opinion, treatment with regorafenib is providing clinical benefit, may continue&#xD;
      the treatment following consultation with the study coordinator and the sponsor.&#xD;
&#xD;
      The Arm B:&#xD;
&#xD;
      Placebo plus BSC until progression (according to RECIST V1.1) intolerance or withdrawal of&#xD;
      consent. Patients who have received placebo will receive open-label regorafenib after&#xD;
      objective tumor progression.&#xD;
&#xD;
      Patients will be stratified at randomization according to histology .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-progression rate</measure>
    <time_frame>8 weeks for cohorts A, B and E, 12 weeks for cohort C, 6 months for cohort D</time_frame>
    <description>Proportion of patients without disease progression at the defined timepoint after central radiological review (using RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>expected average duration of 3 months</time_frame>
    <description>from the date of randomization until the date of radiological progression or death whatever the cause (if death occurs before progression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>complete response (CR) or partial response (PR) according to RECIST 2009, version 1.1, for all cohorts, and CHOI criteria for chordoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>from the date of randomization until the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from the date of randomization until the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>expected average duration of 6 months</time_frame>
    <description>objective response of CR or PR, whichever is noted earlier, to first disease progression or death before progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free rate at 3 and 6 months</measure>
    <time_frame>at 3 and 6 months</time_frame>
    <description>the proportion of patients without progression at 3 and 6 months post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>from date of randomization until the date of first observation of progression (up to 6 months)</time_frame>
    <description>from date of randomization until the date of first observation of progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Modulation Index defined as ratio of time to progressive disease (PD) under regorafenib to time to progression (TTP) under previous treatment</measure>
    <time_frame>expected average duration of 3 months</time_frame>
    <description>ratio of time to PD under regorafenib to TTP under previous treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI-CTCAE V4-0</measure>
    <time_frame>expected average duration of 6 months</time_frame>
    <description>according to NCI-CTCAE V4-0 (National Cancer Institut Common Terminology Criteria for Adverse Events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using Visual analog scale (VAS), DN4 scale (Neuropathic Pain Diagnostic Questionnaire) and NPSI scale (Neuropathic Pain Symptom Inventory)</measure>
    <time_frame>expected average duration of 6 months</time_frame>
    <description>for chordomas cohort only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from date of randomization until the date of first observation of progression (up to 6 months)</time_frame>
    <description>Progression Free Survival according to Choi criteria for Chordoma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Ewing Sarcomas</condition>
  <condition>Chondrosarcomas</condition>
  <condition>Osteosarcomas</condition>
  <condition>Chondroma</condition>
  <condition>CIC-Rearranged Sarcoma</condition>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For adult patients (≥18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .&#xD;
For children Age ≥10 years to &lt;18 years old and BSA ≥1.30 m², regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160 mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity</description>
    <arm_group_label>Regorafenib</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically confirmed diagnosis of bone sarcoma (osteosarcoma,&#xD;
             Ewing sarcoma of bone, chondrosarcoma or chordoma);&#xD;
&#xD;
          2. Patients with confirmed disease progression at study entry;&#xD;
&#xD;
          3. Metastatic disease not amenable to surgical resection or radiation with curative&#xD;
             intent;&#xD;
&#xD;
          4. Patients must have measurable disease;&#xD;
&#xD;
          5. Prior treatment :&#xD;
&#xD;
             at least one, but no more than two prior chemotherapy regimen for metastatic disease&#xD;
             for osteosarcoma, chondrosarcoma and Ewing sarcoma; neo-adjuvant /maintenance therapy&#xD;
             are not counted towards this requirement. Chordoma not pretreated or with 1 or 2 prior&#xD;
             (combination) chemotherapy regimen or with one or two prior molecularly targeted&#xD;
             therapy, but no more than 2 prior lines of treatment (whatever the indication) can be&#xD;
             included. At least 4 weeks since last chemotherapy (6 weeks in case of nitrosoureas&#xD;
             and mitomycin C), immunotherapy or any other pharmacological treatment and/or&#xD;
             radiotherapy;&#xD;
&#xD;
          6. Age ≥10 years for osteosarcomas, Ewing sarcomas and chondrosarcomas (for chordomas,&#xD;
             patients must be ≥18 years);&#xD;
&#xD;
          7. Body Surface Area ≥1.30 m²;&#xD;
&#xD;
          8. Life expectancy of greater than 3 months;&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status &lt;2 (Karnofsky ≥60%) for&#xD;
             adults patients;&#xD;
&#xD;
         10. Karnofsky scale ≥ 60% for children aged &gt;12 years old / Lansky scale ≥60% for children&#xD;
             aged ≤12 years old;&#xD;
&#xD;
         11. Patients must have adequate bone marrow, renal, and hepatic function, as evidenced by&#xD;
             the following within 7 days of study treatment initiation: normal organ function as&#xD;
             defined below:&#xD;
&#xD;
               -  Absolute neutrophil count ≥1.5 Giga/L&#xD;
&#xD;
               -  Platelets ≥100 Giga/L&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Serum creatinin ≤1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) ≥30 ml/min/1.73 m² according to the modified&#xD;
                  Diet in Renal Disease (MDRD) abbreviated formula&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 x ULN&#xD;
&#xD;
               -  Bilirubin ≤1.5 X ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN in patient with liver involvement of&#xD;
                  their cancer). If Alkaline phosphatase &gt;2.5 ULN, hepatic isoenzymes&#xD;
                  5-nucleotidase or gamma-glutamyl transferase (GGT) tests must be performed;&#xD;
                  hepatic isoenzymes 5-nucleotidase must be within the normal range and/or GGT &lt;1.5&#xD;
                  x ULN;&#xD;
&#xD;
               -  lipase ≤1.5 x ULN;&#xD;
&#xD;
               -  Spot urine must not show 1+ or more protein in urine or the patient will require&#xD;
                  a repeat urine analysis. If repeat urinalysis shows 1+ protein or more, a 24-hour&#xD;
                  urine collection will be required and must show total protein excretion &lt;1000&#xD;
                  mg/24 hours&#xD;
&#xD;
         12. International Normalized Ratio(INR)/ Partial Thromboplastin Time (PTT) ≤1.5 x ULN;&#xD;
&#xD;
         13. Recovery to National Cancer Institute-Common Terminology Criteria for Adverse Events&#xD;
             (NCI-CTCAE) v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior&#xD;
             treatment from any previous drug/procedure related toxicity (except alopecia, anemia,&#xD;
             and hypothyroidism);&#xD;
&#xD;
         14. Women of childbearing potential and male patients must agree to use adequate&#xD;
             contraception for the duration of study participation and up to 3 months following&#xD;
             completion of therapy;&#xD;
&#xD;
         15. Women of childbearing potential must have a negative serum β-HCG pregnancy test within&#xD;
             7 days prior randomization and/or urine pregnancy test within 48 hours before the&#xD;
             first administration of the study treatment;&#xD;
&#xD;
         16. Signed informed consent form by adult patients and/or patients parents/legal&#xD;
             representatives (if age &lt;18 years) and age appropriate assent form by the patients'&#xD;
             parents/legal representatives obtained before any study specific procedure is&#xD;
             conducted;&#xD;
&#xD;
         17. Patients must be willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests and other study procedures;&#xD;
&#xD;
         18. Patients or parents/legal representatives affiliated to the Social Security System.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with any VEGFR inhibitor;&#xD;
&#xD;
          2. Soft tissue sarcoma;&#xD;
&#xD;
          3. Other cancer (different histology) within 5 years prior to randomization;&#xD;
&#xD;
          4. Major surgical procedure, open biopsy, significant trauma, within the last 28 days&#xD;
             before randomization;&#xD;
&#xD;
          5. Cardiovascular dysfunction:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt;50%&#xD;
&#xD;
               -  Congestive heart failure (New York Heart Association [NYHA]) ≥2&#xD;
&#xD;
               -  Myocardial infarction &lt;6 months before study&#xD;
&#xD;
               -  Cardiac arrhythmias requiring therapy&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Unstable angina or new-onset angina&#xD;
&#xD;
          6. Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism&#xD;
             within the last 6 months before randomization;&#xD;
&#xD;
          7. Severe hepatic impairment (Child-Pugh C);&#xD;
&#xD;
          8. Ongoing infection &gt; Grade 2 according to NCI-CTCAE v4.0;&#xD;
&#xD;
          9. Known history of human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
         10. Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral&#xD;
             therapy;&#xD;
&#xD;
         11. Difficulties with swallowing study tablets;&#xD;
&#xD;
         12. Prior anticancer therapy, including radiotherapy, endocrine therapy, immunotherapy,&#xD;
             chemotherapy (CT) within the last 4 weeks (6 weeks for nitrosoureas and mitomycin C),&#xD;
             or other investigational agents ; Concomitant antalgic palliative radiotherapy&#xD;
             allowed;&#xD;
&#xD;
         13. Concurrent enrolment in another clinical trial in which investigational therapies are&#xD;
             administered;&#xD;
&#xD;
         14. Known hypersensitivity to the active substance or to any of the excipients;&#xD;
&#xD;
         15. Pregnant women, women who are likely to become pregnant or are breast-feeding;&#xD;
&#xD;
         16. For adult patients, individual deprived of liberty or placed under the authority of a&#xD;
             tutor;&#xD;
&#xD;
         17. Patients with any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial;&#xD;
&#xD;
         18. Patients with history of non compliance to medical regimens or unwilling or unable to&#xD;
             comply with the protocol;&#xD;
&#xD;
         19. Interstitial lung disease with ongoing signs and symptoms at the time of informed&#xD;
             consent;&#xD;
&#xD;
         20. Non-healing wound, non-healing ulcer, or non-healing bone fracture;&#xD;
&#xD;
         21. Patients with evidence or history of any bleeding diathesis, irrespective of severity;&#xD;
&#xD;
         22. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of&#xD;
             study medication;&#xD;
&#xD;
         23. Use of biological response modifiers, such as granulocyte colony stimulating factor&#xD;
             (G-CSF), within 3 weeks of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence DUFFAUD, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Timone University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabrina YARA</last_name>
    <phone>33 (0)85343661</phone>
    <email>s-yara@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Jean Monjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elsa KALBACHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine ITALIANO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14176</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corinne DELCAMBRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alice HERVIEU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas PENEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Yves BLAY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François BERTUCCI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Timone University Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence DUFFAUD, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier CUPISSOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine THYSS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pascaline BOUDOU-ROUQUETTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie PIPERNO-NEUMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe PERRIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de l'ouest site Rene Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth (ICLN)</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier COLLARS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine CHEVREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helene VEGAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de lorraine alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria RIOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier MIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Chondroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no individual participant data is shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

